Literature DB >> 30815886

Movement disorders and nonmotor neuropsychological symptoms in children and adults with classical galactosemia.

Anouk Kuiper1, Stephanie Grünewald2, Elaine Murphy3, Maraike A Coenen4, Hendriekje Eggink1, Rodi Zutt1, Maria E Rubio-Gozalbo5, Annet M Bosch6, Monique Williams7, Terry G J Derks8, Robin H L Lachmann3, Martijn C G J Brouwers9, Mirian C H Janssen10, Marina A Tijssen1, Tom J de Koning1,8.   

Abstract

Although movement disorders (MDs) are known complications, the exact frequency and severity remains uncertain in patients with classical galactosemia, especially in children. We determined the frequency, classification and severity of MDs in a cohort of pediatric and adult galactosemia patients, and assessed the association with nonmotor neuropsychological symptoms and daily functioning. Patients from seven centers in the United Kingdom and the Netherlands with a confirmed galactosemia diagnosis were invited to participate. A videotaped neurological examination was performed and an expert panel scored the presence, classification and severity of MDs. Disease characteristics, nonmotor neuropsychological symptoms, and daily functioning were evaluated with structured interviews and validated questionnaires (Achenbach, Vineland, Health Assessment Questionnaire, SIP68). We recruited 37 patients; 19 adults (mean age 32.6 years) and 18 children (mean age 10.7 years). Subjective self-reports revealed motor symptoms in 19/37 (51.4%), similar to the objective (video) assessment, with MDs in 18/37 patients (48.6%). The objective severity scores were moderate to severe in one third (6/37). Dystonia was the overall major feature, with additional tremor in adults, and myoclonus in children. Behavioral or psychiatric problems were present in 47.2%, mostly internalizing problems, and associated with MDs. Daily functioning was significantly impaired in the majority of patients. Only one patient received symptomatic treatment for MDs. We show that MDs and nonmotor neuropsychological symptoms are frequent in both children and adults with classical galactosemia.
© 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

Entities:  

Keywords:  daily functioning; dystonia; galactosemia; nonmotor symptoms; tremor

Mesh:

Year:  2019        PMID: 30815886     DOI: 10.1002/jimd.12054

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Galactosemia Diagnosis by Whole Exome Sequencing Later in Life.

Authors:  Sara Lucas-Del-Pozo; David Moreno-Martinez; Maria Camprodon-Gomez; Daniel Moreno-Martinez; Jorge Hernández-Vara
Journal:  Mov Disord Clin Pract       Date:  2021-09-03

2.  A galactose-1-phosphate uridylyltransferase-null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue-specific and longitudinal differences in galactose metabolism.

Authors:  Shauna A Rasmussen; Jennifer M I Daenzer; Jessica A MacWilliams; S Taylor Head; Martine B Williams; Aron M Geurts; Jason P Schroeder; David Weinshenker; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2019-12-29       Impact factor: 4.982

3.  The 1-13 C galactose breath test in GALT deficient patients distinguishes NBS detected variant patients but does not predict outcome in classical phenotypes.

Authors:  Mendy M Welsink-Karssies; Dewi van Harskamp; Sacha Ferdinandusse; Carla E M Hollak; Hidde H Huidekoper; Mirian C H Janssen; E Marleen Kemper; Janneke G Langendonk; M Estela Rubio-Gozalbo; Maaike C de Vries; Frits A Wijburg; Henk Schierbeek; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2020-01-22       Impact factor: 4.982

Review 4.  Galactosemia: Towards Pharmacological Chaperones.

Authors:  Samantha Banford; Thomas J McCorvie; Angel L Pey; David J Timson
Journal:  J Pers Med       Date:  2021-02-07

5.  Abnormal N-glycan fucosylation, galactosylation, and sialylation of IgG in adults with classical galactosemia, influence of dietary galactose intake.

Authors:  Eileen P Treacy; Sebastian Vencken; Annet M Bosch; Matthias Gautschi; Estela Rubio-Gozalbo; Charlotte Dawson; Darragh Nerney; Hugh Owen Colhoun; Loai Shakerdi; Gregory M Pastores; Roisin O'Flaherty; Radka Saldova
Journal:  JIMD Rep       Date:  2021-07-22

6.  Metabolic effects of the schizophrenia-associated 3q29 deletion.

Authors:  Rebecca M Pollak; Ryan H Purcell; Timothy P Rutkowski; Tamika Malone; Kimberly J Pachura; Gary J Bassell; Michael P Epstein; Paul A Dawson; Matthew R Smith; Dean P Jones; Michael E Zwick; Stephen T Warren; Tamara Caspary; David Weinshenker; Jennifer G Mulle
Journal:  Transl Psychiatry       Date:  2022-02-17       Impact factor: 7.989

7.  Harnessing the Power of Purple Sweet Potato Color and Myo-Inositol to Treat Classic Galactosemia.

Authors:  Synneva Hagen-Lillevik; Joshua Johnson; Anwer Siddiqi; Jes Persinger; Gillian Hale; Kent Lai
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

Review 8.  Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders.

Authors:  Mahsa Ghasemzad; Mahdieh Hashemi; Zohre Miri Lavasani; Nikoo Hossein-Khannazer; Haleh Bakhshandeh; Roberto Gramignoli; Hani Keshavarz Alikhani; Mustapha Najimi; Saman Nikeghbalian; Massoud Vosough
Journal:  Bioengineering (Basel)       Date:  2022-08-15

9.  Hand fine motor control in classic galactosemia.

Authors:  Jessica MacWilliams; Sneh Patel; Grace Carlock; Sarah Vest; Nancy L Potter; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2021-03-23       Impact factor: 4.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.